Cameron B. Lloyd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cameron B. Lloyd has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Amelia Foss
Department of Oncology and The Milner Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK
75 shared publications - Antonella De Cola
Department of Oncology, University of Cambridge , Cambridge
75 shared publications - Augusto Faria Andrade
Department of Human Genetics, McGill University, Montreal, Quebec, Canada
75 shared publications - Claudia L. Kleinman
Lady Davis Research Institute, Jewish General Hospital, Montréal, Canada
75 shared publications - Damien Faury
Department of Human Genetics, McGill University Health Center Research Institute
75 shared publications - Manav Pathania
Department of Oncology and The Milner Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK
75 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-3, 7-9 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Tables describing statistical analyses, median survivals, IC50 values calculated from cell viability assays, primer sequences and antibodies.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-3, 7-9 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Tables describing statistical analyses, median survivals, IC50 values calculated from cell viability assays, primer sequences and antibodies.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Quality control and filtering of snRNA-seq data.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Quality control and filtering of snRNA-seq data.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-27 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Figures describing hindbrain vs ganglionic eminence targeting strategies, each of the 16 models generated and validation that they expressed the introduced mutations, survival of GE vs CTX-electroporated embryos, and cell viability data shown in bar graph format.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-27 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Figures describing hindbrain vs ganglionic eminence targeting strategies, each of the 16 models generated and validation that they expressed the introduced mutations, survival of GE vs CTX-electroporated embryos, and cell viability data shown in bar graph format.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
SsGEA signatures derived from snRNA-seq data.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
SsGEA signatures derived from snRNA-seq data.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Cell type ontologies derived from snRNA-seq data.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Cell type ontologies derived from snRNA-seq data.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Quality control and filtering of snRNA-seq data.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Quality control and filtering of snRNA-seq data.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
SsGEA signatures derived from snRNA-seq data.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
SsGEA signatures derived from snRNA-seq data.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-27 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Figures describing hindbrain vs ganglionic eminence targeting strategies, each of the 16 models generated and validation that they expressed the introduced mutations, survival of GE vs CTX-electroporated embryos, and cell viability data shown in bar graph format.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-27 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Figures describing hindbrain vs ganglionic eminence targeting strategies, each of the 16 models generated and validation that they expressed the introduced mutations, survival of GE vs CTX-electroporated embryos, and cell viability data shown in bar graph format.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Cell type ontologies derived from snRNA-seq data.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Cell type ontologies derived from snRNA-seq data.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Pediatric high-grade gliomas (pHGGs) are lethal, incurable brain tumors frequently driven by clonal mutations in histone genes. They often harbor a range of additional genetic alterations that correlate with different ages, anatomical locations, and tumor subtypes. We developed models representing 16 pHGG subtypes driven by different combinations of alterations targeted to specific brain regions. Tumors developed with varying latencies and cell lines derived from these models engrafted in syngeneic, immunocompetent mice with high penetrance. Targeted drug screening revealed unexpected selective vulnerabilities— H3.3G34R/PDGFRAC235Y to FGFR inhibition, H3.3K27M/PDGFRAWT to PDGFRA inhibition, and H3.3K27M/PDGFRAWT and H3.3K27M/PPM1DC/PIK3CAE545K to combined inhibition of MEK and PIK3CA. Moreover, H3.3K27M tumors with PIK3CA, NF1 and FGFR1 mutations were more invasive and harbored distinct additional phenotypes, such as exophytic spread, cranial nerve invasion and spinal dissemination. Collectively, these models reveal that different partner alterations produce distinct effects on pHGG cellular composition, latency, invasiveness, and treatment sensitivity.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Pediatric high-grade gliomas (pHGGs) are lethal, incurable brain tumors frequently driven by clonal mutations in histone genes. They often harbor a range of additional genetic alterations that correlate with different ages, anatomical locations, and tumor subtypes. We developed models representing 16 pHGG subtypes driven by different combinations of alterations targeted to specific brain regions. Tumors developed with varying latencies and cell lines derived from these models engrafted in syngeneic, immunocompetent mice with high penetrance. Targeted drug screening revealed unexpected selective vulnerabilities— H3.3G34R/PDGFRAC235Y to FGFR inhibition, H3.3K27M/PDGFRAWT to PDGFRA inhibition, and H3.3K27M/PDGFRAWT and H3.3K27M/PPM1DC/PIK3CAE545K to combined inhibition of MEK and PIK3CA. Moreover, H3.3K27M tumors with PIK3CA, NF1 and FGFR1 mutations were more invasive and harbored distinct additional phenotypes, such as exophytic spread, cranial nerve invasion and spinal dissemination. Collectively, these models reveal that different partner alterations produce distinct effects on pHGG cellular composition, latency, invasiveness, and treatment sensitivity.